Ligands to radiation-induced molecules

Patent metadata

Field	Value
Publication number	US-2016206736-A1
Application number	US-201615094579-A
Country	US
Kind code	A1
Filing date	Apr 8, 2016
Priority date	Oct 3, 2001
Publication date	Jul 21, 2016
Grant date	—

Abstract

A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.

First claim

What is claimed is:

1 . A composition for guided targeting, wherein the composition comprises one or more targeting ligands comprising an amino acid sequence as set forth in Lys-Ala-Arg-Leu-Pro-Pro-Glu-Pro-Ser-Phe-Thr-Val-Phe-Thr-Cys-Gly-Arg-Ala-Ser-Ala (SEQ ID NO:50).

2 . The composition of claim 1 , wherein the one or more targeting ligands bind to one or more of an irradiated glioma, a melanoma, and a lung carcinoma.

3 . The composition of claim 1 , wherein the one or more targeting ligands bind to an irradiated tumor of two or more tumor types.

4 . The composition of claim 3 , wherein the one or more targeting ligands bind to an irradiated tumor of three or more tumor types.

5 . The composition of claim 4 , wherein the one or more targeting ligands bind to an irradiated glioma, a melanoma, and a lung carcinoma.

6 . The composition of claim 1 , wherein the composition further comprises a detectable label, a therapeutic agent, a drug carrier, or combinations thereof.

7 . The composition of claim 6 , wherein the detectable label is an in vivo detectable label that is detectable using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

8 . The composition of claim 7 , wherein the in vivo detectable label comprises a radionuclide label selected from the group consisting of 131 I or 99m Tc.

9 . The composition of claim 6 , wherein the therapeutic agent is selected from the group consisting of a radionuclide, a cytotoxin, a therapeutic gene, and a chemotherapeutic agent.

10 . The composition of claim 6 , wherein the drug carrier is selected from the group consisting of a viral vector, a liposome, a plasmid, a microcapsule, and combinations thereof.

11 . A method for guided delivery of a therapeutic composition, a diagnostic composition, or a combination thereof, to a tumor in a subject, the method comprising:
a. exposing the tumor to ionizing radiation; and b. administering to the subject a therapeutic composition, a diagnostic composition, or a combination thereof, wherein the therapeutic composition, diagnostic composition, or the combination thereof comprises a composition comprising one or more targeting ligands comprising an amino acid sequence as set forth in Lys-Ala-Arg-Leu-Pro-Pro-Glu-Pro-Ser-Phe-Thr-Val-Phe-Thr-Cys-Gly-Arg-Ala-Ser-Ala (SEQ ID NO:50); whereby the therapeutic composition, diagnostic composition, or combination thereof is selectively targeted to the tumor.

12 . The method of claim 11 , wherein the tumor is a primary or a metastasized tumor.

13 . The method of claim 11 , wherein the tumor is selected from a tumor selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head tumor, a neck tumor, and a solid tumor.

14 . The method of claim 11 , wherein the exposing comprises exposing the tumor to at least about 2 Gy ionizing radiation.

15 . The method of claim 11 , wherein the administering comprises administering the targeting ligand by intravascular provision.

16 . The method of claim 11 , wherein the administering comprises administering the targeting ligand subsequent to radiation exposure.

17 . A method of guided delivery of a therapeutic composition, a diagnostic composition, or a combination thereof, to a nucleus of a cell, the method comprising:
a. exposing the cell to ionizing radiation; and b. contacting the cell with a therapeutic composition, a diagnostic composition, or a combination thereof, wherein the therapeutic composition, diagnostic composition, or the combination thereof comprises a composition comprising one or more targeting ligands comprising an amino acid sequence as set forth in Lys-Ala-Arg-Leu-Pro-Pro-Glu-Pro-Ser-Phe-Thr-Val-Phe-Thr-Cys-Gly-Arg-Ala-Ser-Ala (SEQ ID NO:50); whereby the therapeutic composition, diagnostic composition, or combination thereof enters the cell and is selectively targeted to the nucleus of the cell.

Assignees

• Hallahan Dennis E
• Qu Shimian
• Han Zhaozhong
• Univ Vanderbilt
• Univ Washington

Inventors

• Hallahan Dennis E
• Qu Shimian
• Han Zhaozhong

Classifications

• A61K47/48815

  Human Necessities · mapped topic

• A61K41/00 Primary

  Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} · CPC title

• A61K51/088

  conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title

• A61K47/48246

  Human Necessities · mapped topic

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title